We have observed
14 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after April 17, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
ACETYL-CARNITINE FOR USE IN A METHOD FOR INCREASING NEUROGENESIS IN NEURAL TISSUE
COMPOSITION FOR TOPICAL USE FOR TREATING SKIN DISORDERS
COMPOSITION USEFUL FOR THE TREATMENT OF LIPID METABOLISM DISORDERS
Compound useful for preventing cognitive deficit disorders in a new born from HIV-seropositive pregnant female who is in treatment with azidothymidine
PHARMACEUTICAL COMPOSITION OF OXIDISED AVIDIN SUITABLE FOR INHALATION
NEW THIO DERIVATIVES BEARING LACTAMS AS POTENT HDAC INHIBITORS AND THEIR USES AS MEDICAMENTS
COMPOUND HAVING ANTIBACTERIAL ACTIVITY
Physiological supplement or medicament for ophthalmic use containing L-carnitine or alkanoyl L-carnitines in combination with eledoisin
Mildronate in ophthalmic disorders
DITERPENOID DERIVATIVES ENDOWED OF BIOLOGICAL PROPERTIES
THERAPEUTICAL METHOD FOR THE TREATMENT OF THE LEBER OPTIC NEUROPATHY
FOOD AND/OR NUTRACEUTICAL COMPOSITION CONTAINING PEA
COMPOSITION BASED ON COQ10
OROBUCCAL ABSORPTION COMPOSITION FOR NEURO-PROTECTION